July 2021
July’s edition of Small Molecules of the Month, features a selective monovalent estrogen receptor degrader in Ph. III, a remarkable 4(!) neurology clinical candidates from Takeda (including 2 recently licensed by Takeda to Neurocrine, TAK-653 and TAK-041), several oncology clinical candidates including two sulfoximines, and a small molecule that degrades its target via its own ubiquitination.
Thanks to our featured reviewers for their feedback, with special thanks to neuroscience reviewer Jake Schwarz for feedback and commentary on an unusual 5 neuroscience molecules this month.
Search By Structure
Molecules of the Month
2023
2022
2021
2020
Sign up to receive our newsletter!
